JPMorgan Chase & Co. Cuts Repligen (NASDAQ:RGEN) Price Target to $165.00

Repligen (NASDAQ:RGEN) had its target price reduced by JPMorgan Chase & Co. from $180.00 to $165.00 in a research report released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on RGEN. Wells Fargo & Company reduced their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday. HC Wainwright boosted their target price on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $169.62.

Repligen Trading Down 2.3%

Shares of Repligen stock opened at $123.46 on Wednesday. The firm has a 50-day moving average of $121.00 and a 200-day moving average of $144.12. The stock has a market cap of $6.96 billion, a PE ratio of 137.18, a PEG ratio of 2.44 and a beta of 1.09. Repligen has a 52-week low of $109.50 and a 52-week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. Repligen’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts forecast that Repligen will post 1.99 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Measured Wealth Private Client Group LLC acquired a new position in Repligen in the third quarter valued at about $29,000. Bayforest Capital Ltd acquired a new position in Repligen in the fourth quarter valued at about $32,000. Rachor Investment Advisory Services LLC acquired a new position in Repligen in the fourth quarter valued at about $33,000. Los Angeles Capital Management LLC acquired a new position in Repligen in the fourth quarter valued at about $36,000. Finally, CWM LLC raised its stake in Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.